ArticleFrontiers in oncology2023

FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation.

Chaojun Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.